Exscientia

By fusing the power of AI with the discovery experience of seasoned drug hunters, the company says that it is the first to automate drug design, surpassing conventional approaches.

Exscientia's first collaborations include partnerships with UK pharma major GlaxoSmithKline (LSE: GSK) and France's Sanofi (Euronext: SAN), with the former a pre-clinical collaboration focused on up to 10 targets nominated by GSK.

Latest Exscientia News & Features